Cargando…

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial

[Image: see text]

Detalles Bibliográficos
Autores principales:	Rosmarin, D., Smith, S., Shrom, D., Burge, R., See, K., McKean‐Matthews, M., Ridenour, T., Lin, C.‐Y., Gorelick, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060090/ https://www.ncbi.nlm.nih.gov/pubmed/35663140 http://dx.doi.org/10.1002/ski2.43

Ejemplares similares

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey
por: Gorelick, Joe, et al.
Publicado: (2019)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Ixekizumab provides persistent improvements in health‐related quality of life and the sexual impact associated with moderate‐to‐severe genital psoriasis in adult patients during a 52‐week, randomised, placebo‐controlled, phase 3 clinical trial
por: Ryan, C., et al.
Publicado: (2021)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Tungsten and Cobalt: Sheppard et al. Respond
por: Sheppard, Paul R., et al.
Publicado: (2008)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
por: Leonardi, Craig, et al.
Publicado: (2020)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022)

The integration of large-scale public data and network analysis uncovers molecular characteristics of psoriasis
por: Federico, Antonio, et al.
Publicado: (2022)

The authors respond to “Concerns about subgroup analyses and reason for stopping remdesivir trial”
por: Murthy, Srinivas
Publicado: (2022)

Correlation of Psoriasis Disability Index and Psoriasis Area and Severity Index: A Study from Afghanistan
por: Aalemi, Ahmad Khalid, et al.
Publicado: (2022)

The Authors Respond
por: Carlson, Josh J., et al.
Publicado: (2018)

The Authors Respond
por: Touchette, Daniel R., et al.
Publicado: (2020)

To respond or not to respond: exploring empathy-related psychological and structural brain differences between placebo analgesia responders and non-responders
por: Hartmann, Helena, et al.
Publicado: (2023)

THE AUTHORS RESPOND
por: Roth, Joshua A., et al.
Publicado: (2020)

Responding to the evidence for the management of severe malaria
por: Ford, Nathan P, et al.
Publicado: (2011)

Respondent
por: Mitchell, Samuel A.
Publicado: (1992)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2017)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

To respond or not to respond, the recurring question in plant mechanosensitivity
por: Leblanc-Fournier, Nathalie, et al.
Publicado: (2014)

Infant Mental Development Index: Hu et al. Respond
por: Hu, Howard, et al.
Publicado: (2007)

Leishmaniasis recidivans in a nonendemic area that responded to doxycycline
por: Pragna, S, et al.
Publicado: (2020)

Development of an IgG4-RD Responder Index
por: Carruthers, Mollie N., et al.
Publicado: (2012)

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Translation and Validation of the Self-Assessment Psoriasis Area Severity Index
por: Laskowski, Marta, et al.
Publicado: (2023)

HelpResponder—System for the Security of First Responder Interventions
por: Rodriguez-Sanchez, M. Cristina, et al.
Publicado: (2021)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
por: Ashina, Sait, et al.
Publicado: (2023)

The Association between Psoriasis Area and Severity Index and Cardiovascular Risk Factor in Korean Psoriasis Patients
por: Ku, Sang Hyeon, et al.
Publicado: (2016)

Responding to globalization /
Publicado: (2000)

The Author Respond
por: Choi, Jong Sang
Publicado: (2008)

Readers Respond
por: Wig, N.N.
Publicado: (2008)

Readers respond
por: Wig, Narendra N.
Publicado: (2005)

Readers Respond
Publicado: (2004)

Readers Respond
por: Channabasavanna, S. M.
Publicado: (2004)

Readers Respond
Publicado: (2004)

Readers Respond
Publicado: (2004)

Responding to Reviewers
por: Carr, Deborah
Publicado: (2020)

The Authors Respond
por: Traini, Eugenio, et al.
Publicado: (2022)

The Authors Respond
por: Xie, Jipan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_65p4kcqtdrkijaqnvca0a2n5me